Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA) and Shire (NASDAQ: SHPG)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (NASDAQ: AKBA) and Shire (NASDAQ: SHPG) with bullish sentiments.

Akebia Therapeutics (NASDAQ: AKBA)

Aegis Capital analyst Difei Yang reiterated a Buy rating on Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $25. The company’s shares opened today at $15.12, close to its 52-week high of $16.54.

According to TipRanks.com, Yang is a 5-star analyst with an average return of 9.7% and a 50.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Fennec Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.

Shire (NASDAQ: SHPG)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Shire (NASDAQ: SHPG) today and set a price target of $222. The company’s shares opened today at $164.41, close to its 52-week high of $209.22.

Chen observed:

“We expect totals sales for Shire’s HAE franchise to reach $1.9B by 2021. Consensus is only at $1.8B. We think Lanadelumab has peak sales potential of $2B worldwide and the entire HAE franchise has peak sales potential of $2.3B. Shire expects to launch Lanadelumab in 2H18. The product will have a 8-month review at the FDA.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -12.1% and a 39.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.

Shire has an analyst consensus of Moderate Buy, with a price target consensus of $245.20.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.